Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q1 2025 (March 31)10holders −1
0new positions
1sold out
$9.43avg. 13F price*
At the end of Q1 2025, 10 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings, down 1 from Q4 2024. 0 opened new positions and 1 sold out. The largest holders were Frazier Life Sciences Management, L.P. ($4.5M), Ra Capital Management, L.P. ($3.0M) and Affinity Asset Advisors, LLC ($2.7M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $191K |
All 13F filers, Q4 2024 → Q1 2025: 4,022 shares bought and 17,564 shares sold, net −13,542 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $4.5M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $3.0M |
| Affinity Asset Advisors, LLC | — | Add +1.7% | 241,957 | $2.7M |
| Bain Capital Life Sciences Investors, LLC | — | No change | 100,000 | $899K |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $834K |
| Laurion Capital Management LP | — | No change | 16,666 | $150K |
| Vestcor Inc | — | No change | 9,632 | $91K |
| Wolverine Asset Management LLC | — | Reduce -30.0% | 8,884 | $80K |
| UBS Group AG | — | Reduce -4.0% | 2,381 | $21K |
| CIBC Private Wealth Group LLC | — | No change | 1,000 | $6K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.